AXIAL THERAPEUTICS
Live / Registered — Registered (as of 09 Apr 2024)
What this means for you
Registered since 09 Apr 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90217689
- Registration number
- 7355827
- Mark type
- Design + words
- Filed
- 28 Sept 2020
- Published for opposition
- 23 Nov 2021
- Registered
- 09 Apr 2024
- Attorney of record
- Ian W. Gillies
Goods and services
- Class 001 — Chemicals: Chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic or microbe-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic or microbe-targeted pharmaceutical preparations for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
- Class 005 — Pharmaceuticals: Probiotic or microbe-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
- Class 042 — Scientific and technological services: Providing medical and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic or microbe-targeted phamaceutical products; research in the fields of biochemistry, biotechnology, and conducting clinical trials for others
- Class 044 — Medical, beauty and agricultural services: Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic or microbe-targeted pharmaceuticals
Owner
- AXIAL THERAPEUTICS, INC., WOBURN, MA, US
- AXIAL THERAPEUTICS, INC., WOBURN, MA, US
- AXIAL THERAPEUTICS, INC., WOBURN, MA, US
- Axial Biotherapeutics, Inc., Waltham, MA, US
Prosecution history
- 09 Apr 2024 — REGISTERED-PRINCIPAL REGISTER
- 07 Mar 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 06 Mar 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 26 Feb 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Feb 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Feb 2024 — ASSIGNED TO LIE
- 04 Oct 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 18 Jul 2023 — SOU TEAS EXTENSION RECEIVED
- 21 Jun 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 21 Jun 2023 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 04 Apr 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 04 Apr 2023 — NON-FINAL ACTION E-MAILED
- 04 Apr 2023 — SU - NON-FINAL ACTION - WRITTEN
- 06 Mar 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Feb 2023 — USE AMENDMENT FILED